Karyopharm
KPTI
Karyopharm (KPTI) news
Recent news
Karyopharm Therapeutics - Expects FDA decision on Snda filing acceptance in Q4 2026
AInvest Wire · 5h agoKaryopharm Therapeutics - Requests priority review for SNDA to FDA
AInvest Wire · 5h agoKaryopharm 2Q loss/share $2.32
AInvest Wire · Aug 13, 2026Karyopharm Therapeutics Inc: RBC cuts target price to $8 from $16
AInvest Wire · Jul 31, 2026Karyopharm Therapeutics, Inc.: H.C. Wainwright raises to neutral from buy
Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) has seen recent updates in analyst ratings, with H.C. Wainwright revising its stance on the stock. The firm has adjusted its recommendation from "Buy" to "Neutral," reflecting a shift in its assessment of the company’s outlook. This change follows…
AInvest Wire · Jul 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.